> 首页 > 产品 > 一抗 > 基因重组 > Anti-TLR7 Reference Antibody (U.Tokyo patent anti-TLR7)

Anti-TLR7 Reference Antibody (U.Tokyo patent anti-TLR7)

Recombinant Antibody

Anti-TLR7 Reference Antibody (U.Tokyo patent anti-TLR7) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 90%.
The purity of Anti-TLR7 Reference Antibody (U.Tokyo patent anti-TLR7) is more than 95%, determined by SEC-HPLC.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	Q9NYK1
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	120922 Da

Additional Information
Target/Specificity	TLR7
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.

Protein Information
Name	TLR7 (HGNC:15631)
Function	Endosomal receptor that plays a key role in innate and adaptive immunity (PubMed:14976261, PubMed:32433612). Controls host immune response against pathogens through recognition of uridine- containing single strand RNAs (ssRNAs) of viral origin or guanosine analogs (PubMed:12738885, PubMed:27742543, PubMed:31608988, PubMed:32706371, PubMed:35477763). Upon binding to agonists, undergoes dimerization that brings TIR domains from the two molecules into direct contact, leading to the recruitment of TIR-containing downstream adapter MYD88 through homotypic interaction (PubMed:27742543). In turn, the Myddosome signaling complex is formed involving IRAK4, IRAK1, TRAF6, TRAF3 leading to activation of downstream transcription factors NF-kappa-B and IRF7 to induce pro-inflammatory cytokines and interferons, respectively (PubMed:27742543, PubMed:32706371). In plasmacytoid dendritic cells, RNASET2 endonuclease cooperates with PLD3 or PLD4 5'->3' exonucleases to process RNA and release 2',3'-cyclic guanosine monophosphate (2',3'-cGMP) and cytidine-rich RNA fragments that occupy TLR7 ligand-binding pockets and trigger a signaling- competent state.
Cellular Location	Endoplasmic reticulum membrane {ECO:0000250\|UniProtKB:P58681}; Single-pass type I membrane protein {ECO:0000250\|UniProtKB:P58681}. Endosome {ECO:0000250\|UniProtKB:P58681}. Lysosome {ECO:0000250\|UniProtKB:P58681}. Cytoplasmic vesicle, phagosome {ECO:0000250\|UniProtKB:P58681}. Note=Relocalizes from endoplasmic reticulum to endosome and lysosome upon stimulation with agonist {ECO:0000250\|UniProtKB:P58681}
Tissue Location	Detected in brain, placenta, spleen, stomach, small intestine, lung and in plasmacytoid pre-dendritic cells. Expressed in peripheral mononuclear blood cells (PubMed:32706371)